Aptose Biosciences Inc. Files 8-K for Material Agreement
Ticker: APTOF · Form: 8-K · Filed: Feb 3, 2025 · CIK: 882361
Sentiment: neutral
Topics: material-agreement, corporate-filing
Related Tickers: APTO
TL;DR
APTO filed an 8-K for a material agreement. Big news coming.
AI Summary
On February 3, 2025, Aptose Biosciences Inc. filed an 8-K report detailing a material definitive agreement. The company, previously known as Lorus Therapeutics Inc., is incorporated in Canada and operates in the biological products sector.
Why It Matters
This filing indicates a significant contractual development for Aptose Biosciences, which could impact its operations and future business strategies.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant financial or operational risks and opportunities, requiring careful evaluation.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former name
- February 3, 2025 (date) — Date of earliest event reported
- 001-32001 (other) — Commission File Number
FAQ
What is the nature of the material definitive agreement filed by Aptose Biosciences Inc.?
The 8-K filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the header information.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 3, 2025.
What was Aptose Biosciences Inc. formerly known as?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc., and prior to that, Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
What is the SIC code for Aptose Biosciences Inc.?
The Standard Industrial Classification (SIC) code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 949 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2025-02-03 16:46:03
Key Financial Figures
- $1,000,000 — ng an aggregate offering price of up to $1,000,000 and any applicable additional prospectu
Filing Documents
- d894576d8k.htm (8-K) — 28KB
- d894576dex51.htm (EX-5.1) — 13KB
- d894576dex101.htm (EX-10.1) — 207KB
- g894576cm10-11.jpg (GRAPHIC) — 3KB
- g894576g0202235738630.jpg (GRAPHIC) — 2KB
- 0001193125-25-019325.txt ( ) — 446KB
- apto-20250203.xsd (EX-101.SCH) — 3KB
- apto-20250203_lab.xml (EX-101.LAB) — 19KB
- apto-20250203_pre.xml (EX-101.PRE) — 12KB
- d894576d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 3, 2025 APTOSE BIOSCIENCES INC. By: /s/ Fletcher Payne Name: Fletcher Payne Title: Chief Financial Officer